PASSAGE BIO INC. - COMMON STOCK

Passage Bio Announces Positive Interim Clinical Data from First Six Patients with GM1 Gangliosidosis in Imagine-1 Study

14 Dec 2022 07:00:25 By Nasdaq GlobeNewswire

Passage Bio Reports Third Quarter 2022 Financial Results and Provides Business Updates

10 Nov 2022 07:00:02 By Nasdaq GlobeNewswire

Passage Bio to Present at Guggenheim 4th Annual Immunology & Neurology Day

08 Nov 2022 07:00:01 By Nasdaq GlobeNewswire

Passage Bio to Report Third Quarter 2022 Financial Results on November 10, 2022

03 Nov 2022 07:30:00 By Nasdaq GlobeNewswire

Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

14 Oct 2022 16:01:00 By Nasdaq GlobeNewswire

Passage Bio Announces Appointment of William Chou, M.D. as Chief Executive Officer

10 Oct 2022 07:00:00 By Nasdaq GlobeNewswire

Passage Bio to Present at Chardan’s 6th Annual Genetic Medicines Conference

26 Sep 2022 07:00:00 By Nasdaq GlobeNewswire

Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

19 Aug 2022 16:01:00 By Nasdaq GlobeNewswire

Passage Bio Doses First Patient in Global Clinical Trial of PBFT02 Gene Therapy for Frontotemporal Dementia with Granulin Mutations

11 Aug 2022 07:00:02 By Nasdaq GlobeNewswire

Passage Bio to Present at 2022 Wedbush PacGrow Healthcare Virtual Conference

05 Aug 2022 07:00:00 By Nasdaq GlobeNewswire

Passage Bio Reports Second Quarter 2022 Financial Results and Provides Recent Business Highlights

04 Aug 2022 07:00:03 By Nasdaq GlobeNewswire

Passage Bio to Report Second Quarter 2022 Financial Results on August 4, 2022

28 Jul 2022 07:30:00 By Nasdaq GlobeNewswire

Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

21 Jul 2022 16:01:00 By Nasdaq GlobeNewswire

Passage Bio Appoints Michael Kamarck, Ph.D. to Board of Directors

06 Jul 2022 07:00:00 By Nasdaq GlobeNewswire

Passage Bio to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference

09 Jun 2022 07:30:00 By Nasdaq GlobeNewswire

Passage Bio Receives FDA Clearance of IND Application for PBML04 for Treatment of Metachromatic Leukodystrophy

08 Jun 2022 07:30:00 By Nasdaq GlobeNewswire

Passage Bio Announces Leadership Transition

01 Jun 2022 07:30:00 By Nasdaq GlobeNewswire

Passage Bio Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

20 May 2022 16:01:00 By Nasdaq GlobeNewswire

Passage Bio Presents New Interim Clinical and Biomarker Data for Patients with GM1 Gangliosidosis in Imagine-1 Study at ASGCT 25th Annual Meeting

18 May 2022 07:00:00 By Nasdaq GlobeNewswire

Passage Bio Reports First Quarter 2022 Financial Results and Provides Recent Business Highlights

16 May 2022 07:00:01 By Nasdaq GlobeNewswire